The Lausanne-based company plans to use the financing to support further development of its lymphoma drug Zynlonta, including Phase 3 studies combining it with glofitamab in diffuse large B-cell lymphoma and testing it alone in marginal zone lymphoma.

Why it matters: Zealand and Roche are betting that petrelintide’s tolerability can distinguish it in the crowded obesity market. The latest results strengthen that argument, but raise questions about its competitiveness as a standalone treatment for people who also have type 2 diabetes.

Why it matters: The Swiss drugmaker is buying access to a discovery platform, with Defand tasked with finding molecules against multiple disease targets. The approach could help Roche reach proteins that conventional drugs struggle to address.